Most Read Articles
Roshini Claire Anthony, 5 days ago

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Elaine Soliven, 30 Apr 2021
Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Dr Margaret Shi, 5 days ago

The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.

CSF-1R targeted therapies for tenosynovial giant cell tumour: Current landscape and future developments

Dr Margaret Shi
5 days ago

The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.

“At median follow-up of 39 months, the overall response rate [ORR] with pexidartinib was high, at 60 percent as assessed by the Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1, and 65 percent as assessed by tumour volume score [TVS; defined as ≥50 percent reduction in tumour size]. The median duration of response [DoR] was 46.8 months in a pooled analysis of three pexidartinib-treated TGCT cohorts,” reported Dr Tom Wei-Wu Chen of National Taiwan University Cancer Center, Taiwan, at the 4th Chinese University of Hong Kong (CUHK) Sarcoma Masterclass. [Cancer 2021;127:884-893]

The pooled analysis included 130 pexidartinib-treated patients (median age, 45 years; disease location in knee, 57 percent; ≥1 prior surgery, 59 percent; prior systemic therapy, 12 percent) with unresectable and symptomatic TGCT from the phase I PLX108-01 first-in-human extension study (n=39) and multicentre phase III ENLIVEN study (randomized cohort, n=61; crossover cohort, n=30). Treatment-emergent AEs (TEAEs) were mostly of low grade even with long-term treatment. The most common TEAEs were hair colour change (75 percent), fatigue (61 percent), nausea (47 percent), and arthralgia (39 percent). Grade ≥3 increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were reported in 8 percent and 10 percent of the patients, respectively. 

“DCC-3014 is another highly specific, oral CSF-1R inhibitor which exhibits nanomolar potency for CSF-1R. Results of a phase I/II study [dose-escalation phase] of DCC-3014 in 25 patients with TGCT showed promising activity, [with an ORR and partial response rate of 41 percent and 78 percent, respectively],” said Chen. [Razak AA, et al, CTOS Annual Meeting 2020, abstract 38]

“These results are encouraging and support the ongoing phase I/II study [dose expansion phase] in further evaluating the safety and efficacy of DCC-3014 in TGCT patients with or without prior anti-CSF1/CSF-1R treatment. The updated data from the phase I/II study are expected to be presented in the second half of 2021,” Chen added.

“Although rates of all-grade increases in AST were similar between pexidartinib in the pool analysis [31 percent] and DCC-3014 in the phase I study [44 percent], the rate of grade 3/4 increase in ALT was higher with pexidartinib than DCC-3014 [10 percent vs 0 percent],” he continued. [Cancer 2021;127:884-893; Razak AA, et al, CTOS Annual Meeting 2020, abstract 38] 

In the pooled analysis of pexidartinib, elevated AST accounted for 92 percent of liver derangement, with 3 percent of patients experiencing mixed/cholestatic hepatoxicity, which were all reversible (recovery time, 1–7 months). [Cancer 2021;127:884-893]

“TEAEs of pexidartinib, especially liver toxicities, require close monitoring,” Chen suggested.

“Despite the availability of CSF-1R–targeted agents for TGCT, the optimal treatment duration remains unknown. Results of a long-term follow-up study of CSF-1R inhibitors in TGCT patients [n=39] showed a high progression-free survival rate [56 percent] with first-line treatment at a median follow-up of 30 months, suggesting potential benefit with long-term treatment,” Chen continued. [PLoS One 2020;15:e0233046]

“Nevertheless, treatment discontinuation with imatinib mesylate was reported in 66 percent of patients after a median of 7 months, mainly driven by patient’s own decision [24 percent] and need for surgical resection [17 percent],” Chen pointed out. [Sci Rep 2019;9:14551]

“The role of neoadjuvant therapy and systemic therapy in diffuse-type TGCT also needs to be explored further, with respect to the potential in developing treatment resistance,” Chen said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

The combination of nivolumab and platinum chemotherapy in the neoadjuvant setting improved pathological complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC), according to results of the phase III CheckMate-816 trial.

Elaine Soliven, 30 Apr 2021
Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.
31 Mar 2021
At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.
Dr Margaret Shi, 5 days ago

The colony-stimulating factor 1 receptor (CSF-1R) inhibitor pexidartinib is an effective long-term treatment option for adult patients with advanced tenosynovial giant cell tumour (TGCT), but adverse events (AEs), especially liver toxicities, need to be closely monitored. While off-label use of imatinib may be considered in advanced TGCT, development of future-generation CSF-1R inhibitors with an improved AE profile is highly awaited.